Trevena – Consensus Indicates Potential 141.9% Upside

Broker Ratings

Trevena found using ticker (TRVN) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 6 and 5 with the average target price sitting at 5.25. With the stocks previous close at 2.17 this would indicate that there is a potential upside of 141.9%. The 50 day moving average now sits at 2.35 and the 200 day MA is 2.38. The company has a market capitalisation of $328m. Company Website:

Trevena, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index